RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance

被引：0

作者：

Claudia Vollbrecht

Dido Lenze

Michael Hummel

Annika Lehmann

Markus Moebs

Nikolaj Frost

Philipp Jurmeister

Leonille Schweizer

Udo Kellner

Manfred Dietel

Maximilian von Laffert

机构：

[1] Charité-Universitätsmedizin Berlin corporate member of Freie Universität Berlin,Medical Department, Division of Infectiology and Pneumology

[2] Humboldt-Universität zu Berlin,undefined

[3] and Berlin Institute of Health,undefined

[4] Institute of Pathology,undefined

[5] German Cancer Consortium (DKTK),undefined

[6] Geman Cancer Research Center (DKFZ),undefined

[7] Charité-Universitätsmedizin Berlin corporate member of Freie Universität Berlin,undefined

[8] Humboldt-Universität zu Berlin,undefined

[9] and Berlin Institute of Health,undefined

[10] Charité-Universitätsmedizin Berlin corporate member of Freie Universität Berlin,undefined

[11] Humboldt-Universität zu Berlin,undefined

[12] and Berlin Institute of Health,undefined

[13] Charité Comprehensive Cancer Center,undefined

[14] Johannes Wesling Klinikum Minden,undefined

[15] Institute for Pathology,undefined

[16] Berlin Institute of Health (BIH),undefined

来源：

BMC Cancer | / 18卷

关键词：

Non-small cell lung cancer (NSCLC); Anaplastic lymphoma kinase (ALK); Fluorescence in-situ hybridization (FISH); Immunohistochemistry (IHC); Massive parallel sequencing (MPS); NanoString;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 214 条

[1]

Soda M(2007)Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561-566

[2]

Choi YL(2018)Immunohistochemistry of pulmonary biomarkers: a perspective from members of the pulmonary pathology society Arch Pathol Lab Med 142 408-419

[3]

Enomoto M(2013)Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Arch Pathol Lab Med 137 828-860

[4]

Takada S(2014)Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer Ann Oncol 25 1681-1690

[5]

Yamashita Y(2012)Consensus statement on testing for EML4-ALK in non-small-cell carcinomas of the lung Virch Arch 461 245-257

[6]

Thunnissen E(2011)Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 1004-1012

[7]

Allen TC(2010)Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 1693-1703

[8]

Adam J(2016)ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm J Thorac Oncol 11 487-495

[9]

Aisner DL(2014)Multicenter Immunohistochemical ALK-Testing of Non-Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria J Thorac Oncol 9 1685-1692

[10]

Beasley MB(2013)New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC-in situ hybridization assay J Thorac Oncol 8 1019-1031

← 1 2 3 4 5 6 7 8 9 10 →